Why Acadia Pharmaceuticals Stock Is Crushing It Today

Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) are soaring today, up 17.8% as of 11:27 a.m. EDT, after the drugmaker announced strong second-quarter financial results. 

The main reason investors are so pumped up about Acadia is due to just how impressive the company's Q2 results were. Acadia reported that its revenue in the second quarter increased 46% year over year to $83.2 million, fueled by continued momentum for antipsychotic drug Nuplazid. This easily topped the consensus Wall Street estimate of a little over $72 million in revenue.

Image source: Getty Images.

Continue reading

Quelle Fool.com